Zymeworks Inc. has made an important amendment to its previous SEC filing, providing detailed financial statements related to its recent acquisition of Theravance Biopharma, Inc. This update, filed on November 9, 2026, clarifies the financial implications of the merger, which is significant for the pharmaceutical preparations sector.
The amendment comes after Zymeworks completed the merger with Theravance, a move that is expected to enhance its portfolio and market position. The filing includes historical financial statements of Theravance and pro forma financial information, offering a clearer picture of the financial landscape following the merger.
Background
Zymeworks Inc. is a Delaware-based company primarily engaged in the pharmaceutical preparations industry, as classified under SIC 2834. The company trades on the Nasdaq under the ticker symbol ZYME. Recent filings indicate Zymeworks is a smaller reporting company and a non-accelerated filer. Its latest filings include a 10-Q and an 8-K, both filed on November 9, 2026, detailing its financial results and the merger.
What the Filing Says
The amended filing provides crucial financial data that was previously omitted. According to the filing, "This Current Report on Form 8-K/A amends the Original Form 8-K to provide the historical financial statements and pro forma financial information required by Item 9.01 of Form 8-K." The amendment includes audited financial statements of Theravance for the years ended December 31, 2025, and 2024, as well as unaudited interim financial statements for the six-month periods ended June 30, 2026, and 2025.
Impact
This filing may significantly affect investors, analysts, and stakeholders interested in Zymeworks and the broader pharmaceutical preparations industry. The detailed financial information will help stakeholders assess the financial health of the combined entity and its future growth potential. With the merger, Zymeworks aims to leverage Theravance's assets to enhance its product offerings and market reach.
What's Next
The filing does not say what happens next, but the inclusion of these financial statements is expected to facilitate a smoother integration process and provide clarity for future financial reporting.
Source: SEC Accession Number 0001193125-26-453730
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










